The U.S. Food and Drug Administration (FDA) has granted orphan drug status (ODD) to Catalyst Biosciences’ highly potent recombinant human factor IX variant CB 2679d (also known as ISU304) to treat hemophilia B. Catalyst is evaluating CB 2679d’s potential for subcutaneous prophylactic treatment in people with hemophilia B. The regulatory decision…

Catalyst Biosciences recently announced that its collaborator, ISU Abixs, has completed dosing of the first subcutaneous cohort in an ongoing Phase 1/2 proof-of-concept clinical trial in people with severe hemophilia B. This patient group is the second of up to five involved in the study. CB 2679d (also known as ISU304)…

https://www.youtube.com/watch?v=qKRqJWVQRio This video from the Centers for Disease Control and Prevention takes a look at hemophilia and explains what the blood disorder means for those who suffer from it. MORE: Three tips for coping with a hemophilia diagnosis Hemophilia patients and caregivers share how hemophilia affects their everyday lives…

The Hemophilia Foundation of American (HFA) has teamed up with the Centers for Disease Control and Prevention (CDC) to create a survey for hemophilia and bleeding disorder patients who don’t currently receive care from a government-funded hemophilia treatment center (HTC). MORE: Why shared data is important for furthering hemophilia research…

Hemophilia is a rare blood disease that usually occurs in males. In fact, it’s extremely rare for women to be born with the condition because of the way it’s passed down genetically. A female would need to inherit two copies of the faulty gene — one from each parent —…

Life with hemophilia can be challenging but there are ways that you can manage the disease to ensure your child leads as normal a life as possible. To help you navigate your child’s illness and help prevent bleeds, we’ve put together a list of tips. MORE: How to prepare for your child’s…

Results of the first group of patients with hemophilia B treated with Catalyst Biosciences’ lead candidate CB 2679d in a Phase 1/2 clinical trial demonstrated its improved stability and activity compared to Pfizer’s BeneFix standard-of-care replacement therapy. CB 2679d (also known as ISU304), was designed to be the…

Hemophilia is a rare blood condition where people do not have the clotting factor that enables their blood to clot when bleeding. It’s an inherited disease that’s usually passed from mother to son. It’s also a disease that’s been prevalent in European royal families. MORE: A brief history of hemophilia…

This children’s video from Centers for Disease Control and Prevention focuses on how to tell your friends that you have hemophilia. MORE: How kids can play safe with hemophilia Billy, a young boy with hemophilia, answers some of the questions that his friends ask about the disease. He…

A new online service allows patients with bleeding disorders like hemophilia to share important information about their treatment and bleeds with their healthcare team in real time. MORE: Five tips for living healthily with hemophilia The HemaGo XChange portal was created by Novo Nordisk A/S as an update to their existing website…